aidsmap news story
Several studies presented at AIDS 2026 dealt with vaccines designed to counteract a phenomenon that has limited their efficacy in the past – immunodominance.
Immunodominance is the immune system’s tendency to focus on the most conspicuous parts of a virus. With HIV, those parts act like decoys: they vary freely from one virus to the next, so antibodies against them work on few other strains.
Effective antibodies, on the other hand, are able to target epitopes that are parts of essential viral mechanisms and are therefore hard to change (‘conserved’). These are often hidden from the surveillance of the immune system, either by only being exposed during brief moments of change, or through camouflage – in the case of HIV by a cloak of sugar molecules (glycans).
Two studies presented at AIDS 2026 demonstrated different ways of designing vaccines to overcome the problem of immunodominance.
Read the full news story here.
View all aidsmap reports from AIDS 2026
Explore further: Full coverage of AIDS 2026
Source : aidsmap
Related HIV and Co-Infections News
-
[AIDS 2026] aidsmap: ‘We finally understand what we have to do’: antibody studies point the way to an HIV cure
-
[AIDS 2026] aidsmap: A new class of drugs could sharpen the body’s immune response to HIV
-
UC Davis School of Medicine: Probiotic-derived bioactive metabolite reverses gut dysfunction and boosts HIV treatment response
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.